Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB publishes encouraging Neupro trial data

UCB publishes encouraging Neupro trial data

23rd November 2010

UCB has highlighted new data from a clinical trial which demonstrates some of the benefits its Neupro treatment can offer to Parkinson's disease sufferers.

Findings from the recent Recover study have been published in the Movement Disorders medical journal, showing that Neupro can play a key role in improving motor function, sleep and non-motor symptoms.

This conclusion was drawn following a placebo-controlled trial involving 287 Parkinson's patients with unsatisfactory early-morning motor symptom control, in which the coprimary efficacy outcome targets were met.

Furthermore, a number of secondary improvements were also observed in terms of sleep quality, pain, depression and daily living standards.

Dr Claudia Trenkwalder, professor of neurology at University of Goettingen and the lead Recover study investigator, said: "Sleep disturbance, impairment of early morning motor function and health-related quality of life are common and important nocturnal, early-morning and daytime problems for Parkinson's disease patients."

Neupro was one of UCB's bestselling drugs in the third quarter of 2010, helping the company to achieve year-on-year revenue growth of nine percent.ADNFCR-8000103-ID-800250826-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.